Acta Pharm. 69 (2019) 423-431
Short communication
Inhibitory effect of
taspine derivative TAD1822-7 on tumor cell growth and angiogenesis via suppressing EphrinB2 and related signaling
pathways
RUI LIU, RUNZE YU, YUXIN CUI, MENGYING FAN, BO WANG AND YANMIN ZHANG
School of Pharmacy, Xi'an Jiaotong University, 710061
Xi'an, Shaanxi, China
Accepted December 3, 2018
Published online December 22, 2018
The aim of this study was to investigate the inhibitory effect of TAD1822-7, a
synthesized taspine derivative, on cancer
through its effects on tumor cell growth and angiogenesis
via
suppression of
EphrinB2. The obtained data showed
that TAD1822-7
decreased Bel-7402 cell viability and colony formation
ability and suppressed cell migration. TAD1822-7
effectively inhibited blood vessel formation in an
aortic ring assay to examine angiogenesis. Moreover, it also
downregulated the expression of VEGFR2, VEGFR3, CD34, PLCγ, Akt, MMP2,
MMP9, and CXCR4, and suppressed the expression of EphrinB2 and its PDZ protein,
PICK1, in Bel-7402 cells. These results indicate that TAD1822-7 is a potential
anti-angiogenic agent that can inhibit the viability and migration of Bel-7402
cells via
suppression of EphrinB2 and the related signaling pathways.
Keywords: TAD1822-7, EphrinB2, Bel-7402
cells, proliferation, migration, anti-angiogenesis